Chiome Bioscience Inc. announced that ADC Therapeutics SA ('ADCT') has entered into a license agreement with Chiome for the development and commercialization of an Antibody Drug Conjugate (ADC) incorporating the anti-DLK-1 antibody, LIV-1205, developed by Chiome. Under the License Agreement, ADCT obtains the exclusive, worldwide, and sublicensable rights to the anti-DLK-1 antibody in the ADC field. Chiome retains the rights to develop an anti-DLK-1 antibody outside the field of ADC, and Chiome will continue making efforts to develop and license out such product to pharmaceutical companies. Chiome will be entitled to an up-front payment following execution of the License Agreement for LIV-1205, and to contingent development and sales milestone payments as well as royalties on eventual sales.